BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Paragon Bioservices 

801 West Baltimore Street
Suite 401
Baltimore  Maryland  21201  U.S.A.
Phone: 800-545-6569 Fax: 410-605-2028


SEARCH JOBS
Paragon Bioservices, Inc. is a contract research and GMP manufacturing organization (CRO, CDMO, CMO) that is focused on the development and manufacturing of biopharmaceuticals—either for research purposes or clinical trials. Working as an outsourcing partner and with a long-standing tradition of quality and service, Paragon expands the capabilities of pharmaceutical companies, biotechnology companies and federal agencies involved in the development of Monoclonal Antibodies, Therapeutic Proteins, Vaccines (VLPs) and Stem Cell-Based Therapeutics.

Industry trends and national imperatives include active consolidation in pharmaceutical companies, the advent of virtual biotechnology companies and the need for national preparedness. All of these continue to fuel the need for outsourcing—an all-encompassing practice that, today, includes the entire drug development paradigm: from the discovery bench through process development to GMP manufacturing of drug products for clinical trials. Therefore, Paragon’s corporate strategy is to provide better integration of our offerings to meet the “programmatic outsourcing needs” of our clients.

Our strategy is also to identify niche opportunities and to become the best organization to go to for R&D services and GMP manufacturing of vaccines-VLPs, monoclonal antibodies and stem cell technologies. In addition, we will continue to build infrastructure—while protecting our clients’ intellectual property through domestic R&D and manufacturing.

Founded in 1990, Paragon Bioservices is located at the University of Maryland BioPark in Baltimore. The state of Maryland is one of the best-recognized epicenters of biotechnology in the the world today—as well as home to The FDA, USDA, NIH, NIST, National Cancer Institute and a wealth of major universities. Baltimore itself is home to the world-renowned Johns Hopkins and The University of Maryland School of Medicine. Having access to these institutions—for expertise, consultation, sophisticated analytics, and a vast source of talented personnel—enhances the value of our CMO services and makes Paragon unique among its peers. Maryland is also home to hundreds of biotechnology companies that include AstraZeneca/MedImmune and Human Genome Sciences.

Paragon is focused on continuing to deliver research-grade proteins, process development services, GMP manufacturing (both microbial and mammalian platforms) and cell therapies for Phase I/II clinical trials. Our focus on biologics and efficient integration of single-use technologies allows us to keep our overhead low (as compared to other CMOs, who also provide Phase III and commercial manufacturing). We are agile, creative in problem-solving, flexible, and able to quickly engage additional shifts or added staff—in order to meet aggressive timelines.

Paragon’s business model relies on three independent revenue sources: preclinical services, GMP manufacturing and government contracting—our client base is distributed among pharmaceutical and biotechnology companies (75%) and federal agenices (25%).

Paragon is financially stable and it is presently in the midst of an expansion. Upon completion in 4Q11, the facility will have a total of 52,000 sq ft of state-of-the-art laboratories and manufacturing suites.

Key management listings
• Marco A. Chacon, PhD – President & CEO
• Robert Eberwein – Senior Vice President, GMP Operations
• Vadim Klyushinichenko – Vice President, Preclinical Services & Process Development
• Ronald A.J. Wilson - CFO

Company You Tube Video.


 Key Statistics


Email: sales-support@paragonbioservices.com
Ownership: Private

Web Site: Paragon Bioservices
Employees:
Symbol: 
 









 Company News
Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of Its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of Its Anthrax Vaccine 11/5/2013 9:29:44 AM    More...
Paragon Bioservices Wins CMO Leadership Awards for Third Consecutive Year 9/10/2013 9:39:02 AM    More...
MaxCyte, Inc.® VLX™ and STX™ Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing 1/29/2013 9:45:31 AM    More...
Paragon Bioservices Wins the 2012 CMO Leadership Award 8/2/2012 11:14:50 AM    More...
Paragon Bioservices Awarded Multi-Million Dollar DoD Contract for Filovirus Vaccine Development and Manufacturing 1/18/2012 9:51:40 AM    More...
Paragon Bioservices Appoints Dr. Vadim Klyushnichenko as Vice President of Preclinical Services and Process Development 7/20/2011 11:16:08 AM    More...
Paragon Bioservices to Partner and Exhibit at the 2011 BIO International Convention 6/9/2011 8:53:16 AM    More...
The University of Maryland, Baltimore and Paragon Bioservices Announce the Formation of a Public-Private Stem Cell Technology Consortium 4/28/2011 9:27:25 AM    More...
Neurotez, Inc., Announced That It Has Contracted with Paragon Bioservices for the Manufacturing of a Leptin Product for the Treatment of Alzheimer's Disease and Other Cognitive Disorders 12/20/2010 9:05:58 AM    More...
Paragon Bioservices Launches Second Expansion to Celebrate its 20th Anniversary 10/27/2010 11:22:48 AM    More...
12

//-->